Fig. 1: Verlindamycin inhibits neuroblastoma cell proliferation and enhances growth-inhibitory effect of ATRA. | Cancer Gene Therapy

Fig. 1: Verlindamycin inhibits neuroblastoma cell proliferation and enhances growth-inhibitory effect of ATRA.

From: The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme

Fig. 1: Verlindamycin inhibits neuroblastoma cell proliferation and enhances growth-inhibitory effect of ATRA.

A Structure of verlindamycin. B Dose response by SRB assay for a panel of non MYCN-amplified (blue) and MYCN-amplified (red) neuroblastoma cell lines treated with verlindamycin for 72 h. 50% growth-inhibitory (GI50) values are shown for individual cell lines (left panel) and non-MYCN-amplified versus MYCN-amplified cell lines (right panel). C SK-N-BE(2)-C and Kelly cells cultured as tumor spheroids were treated with verlindamycin for 72 h and changes in spheroid diameter were assessed using a Celigo S Imaging Cell Cytometer. D Viability assessment as measured by CellTiter Glo (Promega) in SK-N-BE(2)-C and Kelly cells grown in monolayer. Metabolic activity of cells treated with 0.5× GI50 verlindamycin in combination with 1 μM ATRA was measured by CellTiter Glo after 6 days of treatment. E Cells treated with 0.5× GI50 verlindamycin and 1 μM ATRA for 10 days were tested for their ability to form colonies from single cells within 14 days. All the experiments were performed in triplicates and a representative result or mean is shown. Student’s t test was performed to calculate statistical significance, *p < 0.05, **p < 0.005, ***p < 0.0005, error bars show standard deviation.

Back to article page